SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children
Provided By GlobeNewswire
Last update: Sep 29, 2025
Data show results consistent with clinical trial experience
A high level of safety – no device-related adverse events
Strong survival data extending to 90 days
